MLXIPL and metabolic dysfunction-associated steatotic liver disease: LGG treatment raises hepatic FGF21 expression and serum ADPN concentration, which reduces ChREBP activation via dihydrosphingosine-1-phosphate-mediated PP2A deactivation, and thereby reverses fructose-induced NAFLD.